LIXTE Appoints Bas Van Der Baan As President And Chief Executive Officer, Effective September 26, 2023
Portfolio Pulse from Benzinga Newsdesk
LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) has announced the appointment of Bas van der Baan as President and Chief Executive Officer, effective from September 26, 2023. Mr. van der Baan, who has over 20 years of experience in the biotechnology industry, will succeed John S. Kovach, the company's founder. Dr. Kovach will continue as the company's Chief Scientific Officer. Mr. van der Baan was previously the Chief Clinical and Business Development Officer of Agendia, Inc.
September 26, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The appointment of Bas van der Baan as President and CEO of LIXTE Biotechnology Holdings could potentially bring new strategic directions and partnerships for the company, given his extensive experience in the biotechnology industry and previous role at Agendia, Inc.
Given Mr. van der Baan's extensive experience in the biotechnology industry and his previous role at Agendia, Inc., his appointment as President and CEO could potentially bring new strategic directions and partnerships for LIXTE. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100